Blockchain Registration Transaction Record

Soligenix Reports Positive Phase 2a Results for Psoriasis Therapy SGX302

Soligenix announces positive Phase 2a results for SGX302 psoriasis therapy showing safety and efficacy with optimized gel formulation in clinical trial extension cohort.

This news matters because it represents significant progress in developing safer treatment options for the approximately 125 million people worldwide affected by psoriasis. Current treatments often carry risks of carcinogenicity or systemic side effects, creating an urgent need for noncarcinogenic alternatives like SGX302's photodynamic therapy approach. The positive safety profile and clinical improvements observed in the Phase 2a trial suggest this could become an important new option for patients with mild-to-moderate psoriasis who seek effective local treatment without systemic risks. For the broader healthcare landscape, successful development of such therapies could reduce long-term healthcare costs associated with managing side effects of current treatments while improving patient quality of life through more convenient, targeted therapeutic approaches.